福森藥業(01652.HK)上半年淨利上升約47.7%至3490萬元 中期息0.45分
格隆匯 8 月 31日丨福森藥業(01652.HK)發佈公告,2020年上半年,集團收益同比上升約26.0%至約人民幣2.475億元;毛利同比上升約24.3%至約人民幣1.328億元;公司股權持有人應占溢利同比上升約47.7%至約人民幣3490萬元;基本每股盈利人民幣4分;擬派中期股息每股普通股人民幣0.45分。
公告表示,2020年上半年,集團收益同比上升約26.0%至約人民幣2.475億元,主要是由於銷量增加所致。在集團的產品類別中,雙黃連口服液的銷售收益同比上升約55%至約人民幣1.548億元,主要是由於中國國內市場需求激增所致。雙黃連注射液的銷售收益同比減少約33.4%至約人民幣2460萬元,主要是由於有關注射液的藥品監管的持續影響所致。集團來自其他產品的收益同比微增約13.7%至約人民幣4890萬元,主要由於集團持續推廣所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.